FDA Accepts Supplemental NDA for ZORYVE (Roflumilast) by Arcutis
The FDA has accepted a supplemental NDA for ZORYVE, which contains the active ingredient roflumilast.
Asset / Drug
Drug and asset intelligence for Arcutis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.